Thibaud Kössler, MD, PhD, on Localized Rectal Cancer: Neoadjuvant Pembrolizumab and Radiotherapy

January 28, 2020 By The ASCO Post

Thibaud Kössler, MD, PhD, of Geneva University Hospital, discusses the first trial to study the efficacy and safety of anti–PD-1 immunotherapy plus short-course radiotherapy in localized microsatellite-stable rectal cancer. The study explores whether a gene signature can predict sensitivity to immunotherapy (Abstract TPS272).

Related Content